AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04836507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study NCT04917367 — intervention group
Intervention type: PROCEDURE
Intervention: exploratory surgery
Description: For foreign bodies in the retropharyngeal space or parapharyngeal space above the esophageal entrance, close to the laryngopharynx cavity with large operating space, suspension laryngoscopy is the first choice according to the principle of proximity. In all cases, a lateral cleft laryngoscope was used to expose the posterior or lateral wall of the laryngopharynx, and 30° endoscope or microscope was used according to the skills of the surgeon.~For a foreign body below the esophageal entrance, the lateral cervical incision was the first choice due to the small operating space of oral exposure. The lateral cervical incision and other open surgical methods are used for foreign bodies below the entrance of the esophagus or in the submaxillary space or for the anterior cervical band muscle foreign bodies.
Study NCT04839393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 followed by PF-06882961/PF-06865571
Description: Treatment A - PF-06882961 20 mg single dose followed by Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose. There will be a washout interval between periods of at least 3 days.
Study NCT04839393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961/PF-06865571 followed by PF-06882961
Description: Treatment B - PF-06882961 20 mg single dose plus PF-06865571 300 mg single dose followed by Treatment A - PF-06882961 20 mg single dose. There will be a washout interval between periods of at least 3 days.
Study NCT04839393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961 + PF-06865571
Description: Period 1: PF-06865571 300 mg single dose (Day 1), Period 2: PF-06882961 10 mg twice daily dose titration up to 200 mg twice daily dosing (Days 3-46), Period 3: PF-06865571 300 mg single dose (Day 47) and PF-06882961 200 mg twice daily dosing (Days 47-48), Period 4: PF-06865571 300 mg twice daily dosing and PF-06882961 200 mg twice daily dosing (Days 49-62)
Study NCT06020833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat in combination with retinoic acid
Description: Roxadustat 150mg po qod combined with retinoic acid 20mg po bid
Study NCT04021485 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neurodevelopmental assessment
Description: As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 5 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~* Standardized neurological exam~* Morphometric measurements including height, weight, head circumference~* Blood pressure measurement~* Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY-II subtests,~* Social Relativeness, using Social Relativeness Scale parental questionnaire,~* Parental stress using PSI questionnaire
Study NCT06287541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine biomarker -Guided without reTURBT
Description: Participants will proceed without reTURBT
Study NCT04898127 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 antigen rapid test
Description: Rapid test before access to mass gathering event (concert), provided the test result is negative.
Study NCT06423872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT002
Description: Participants will receive a single subcutaneous (SC) ZT002 injection.
Study NCT06423872 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive same volume as of the study drug.
Study NCT05660889 — intervention group
Intervention type: OTHER
Intervention: Blood sampling.
Description: Blood samples from both study groups, taken during an adrenal vein sampling, will be compared across the groups.
Study NCT06349850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum uric acid level to plasma HDL-c level ratio (UHR)
Description: high UHR is considered to be a risk factor for development of DKI in type 2 DM
Study NCT05833009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
Study NCT05833009 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: All the groups receive respective treatment 3 times a week for the first eight weeks, twice a week for another 8 weeks, and once a week for the last 4 weeks.
Study NCT05836116 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Muscle Activation
Description: Evaluation of Muscle Activation The sEMG device, which is a surface EMG system (Myomonitor, Delsys Inc, Boston, MA), was used to measure the lateral and medial muscle activation levels of the latissimus dorsi.~Electrode placement was determined according to SENIAM (Surface Electromyography for Non-Invasive Evaluation of Muscles) criteria.~Evaluation of the Gibbosity Trunk rotation (gibbosity) assessments were performed using Adam's test and using a scoliometer . The bending test (Adam's test) is performed in both standing and forward bending positions. The standing version was used in our study.Each measurement equal to 0° on the scoliometer was defined as symmetry at the measured level of the trunk. All other scoliometer values were defined as asymmetry.~Evaluation of the Cobb Angle Cobb angles of the curves of the individuals participating in the study were measured with the MicroDicom application.
Study NCT04995627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salt (NaCl)
Description: 12 grams of salt (NaCl) per day
Study NCT05511506 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: aqueous humor collection
Description: Once the laser procedures were finished, the patient was transported to another surgery operating bed. Before the eyeball was opened, 100-200 μL of aqueous humor was obtained from the anterior chamber via an ultra-thin needle through the paracentesis site of cornea.
Study NCT04631952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online exercise
Description: SMS messeages on encouraging active lifestyle and online exercise video will be sent to the participant weekly for 8 weeks.
Study NCT04631952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS message
Description: SMS messeages on encouraging active lifestyle will be sent to the participant weekly for 8 weeks.
Study NCT04995627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06483321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Normocaloric vegan diet supplemented with 0.1 g/kg/day of creatine monohydrate~Normocaloric diet based solely on foods of plant sources with creatine supplementatio (0.1 g/kg/day)
Study NCT06483321 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normocaloric vegan diet supplemented with 0.1 g/kg/day of placebo (maltodextrin)
Study NCT05001932 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Randomized Clinical Trial
Study NCT05352347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.2 mg/kg
Description: NuSepin® 0.2 mg/kg in 100mL NS bid
Study NCT06502522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: Symmetrical biphasic current, pulse width of 400 μs, frequency of 75 Hz, contraction time of five seconds and rest time of 10 seconds. The intensity will be individually adjusted to the patient's maximum tolerance limit to reach the motor threshold and the volunteer will be instructed to achieve a score of 7 on the modified BORG scale to ensure a moderate-intense effort. The session time will be 16 minutes, resulting in a total of 64 contractions per session. The progression of overload will only occur with an increase in the intensity of all muscle groups during the sessions.~Concomitantly with the electrical stimuli, the volunteer will perform exercises for the upper, lower limbs and trunk. After performing neuromuscular electrical stimulation, the patient will remain in the supine position to receive sensory stimulation throughout the body. The parameters used will be: frequency of 20 Hz and pulse width of 400 μs for 44 minutes.
Study NCT06424821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Cadonilimab + chemotherapy
Study NCT05860907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier Granule
Description: 10g each time, three times a day
Study NCT05937386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGMB-129
Description: Oral capsule
Study NCT05937386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDZ
Description: Pre-filled oral syringes
Study NCT06425913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping (KT)
Description: KT was applied to the symptomatic shoulder at the end of the baseline assessment by a certificated physiotherapist with over ten years of experience in Kinesio taping. After three days, participants were re-evaluated. KT application has been made according to the protocol for rotator cuff impingement or tendonitis including inhibition and correction techniques.
Study NCT06425913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Therapy (CT)
Description: The initial application was administered by the physiotherapist. In a sitting position, a pack was wrapped in a thin towel and placed on the affected shoulder joint, including the painful locations. During the application, the participant was closely observed for discomfort or adverse reactions (redness, burning, numbness, itching, ...). The cold application was continued for 20 minutes.After the first application, participants were instructed to apply ice for 20 minutes five times a day for three days at home or work.
Study NCT06425913 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized home exercise program
Description: All participants performed standardized home exercise program, including shoulder isometric and stretching exercises were . A physiotherapist taught the exercise program until the participants were able to exercise accurately on their own. All participants were instructed to perform the exercises three times a day for three days.
Study NCT04744948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Description: high intensity interval training
Study NCT04744948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low caloric diet
Description: low caloric diet (1200ca/lday)
Study NCT04744948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: low caloric diet (1200ca/lday)
Study NCT06422624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 1 mg
Description: Singel-dose; Subcutaneous
Study NCT06422624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 4 mg
Description: Singel-dose; Subcutaneous
Study NCT06422624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Extended-release for Injectable Suspension, 8 mg
Description: Singel-dose; Subcutaneous
Study NCT05482945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noble gas Argon
Description: Ventilation with Ar 70%/O2 30% in comatose patients resuscitated from OHCA with the use of an experimental mechanical ventilator.
Study NCT05664204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Veno-arterial extracorporeal membrane oxygenation
Description: Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
Study NCT05664204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Veno-arterial extracorporeal membrane oxygenation
Description: Strategy would reduce the need for invasive mechanical ventilation in the first 28 days without increasing adverse events
Study NCT05352347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.4 mg/kg
Description: NuSepin® 0.4 mg/kg in 100mL NS bid
Study NCT05352347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (NS) 100mL bid
Study NCT05062902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device
Description: A personalized, precision botulinum neurotoxin injection guidance medical device, utilizing an intra-vaginal high-density surface EMG system to optimize the treatment outcomes in chronic pelvic pain (CPP) management.
Study NCT05062902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
Study NCT05062902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Neurotoxin
Description: Botulinum neurotoxin will be injected into the pelvic floor muscles following either a standard template (standard injection arm), or guided using high-density surface EMG (guided arm).
Study NCT05243953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levcromakalim
Description: Study participants will be allocated to receive continuous intravenous infusion of 0.05 mg/min (20 ml of 50 mg/ml) levcromakalim.
Study NCT05243953 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study NCT04709913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study NCT04709913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HU6
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study NCT06452368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: Fixation of miniplates by four screws in the maxilla and protraction by using facemask
Study NCT06271382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure Group
Description: In the research, the participant in the acupressure group will receive acupressure application 3 times a week for 2 weeks, a total of 6 times.~Depending on the preparation and pressure time on the 5 selected points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.
Study NCT06271382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Acupressure Group
Description: Depending on the preparation and pressure time on the 5 selected sham points (a total of 10 points will be applied since the partner of each point on the other extremity will be applied), the session duration for an individual will be approximately 18-20 minutes.~Patients in the sham acupressure group will receive acupressure 6 times in total, 3 times a week for 2 weeks. The practitioner will do the first acupressure at the Family Health Center, and the person with type 2 diabetes will do the others at home. Ankle Brachial Index evaluation will be performed by the researcher at the Family Health Center a total of 3 times before the intervention, 1 week after the intervention and 2 weeks after the intervention.
Study NCT06271382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Ankle Exercise Group
Description: Exercise will be performed regularly for 2 weeks, 3 days a week for a maximum of 30 minutes.
Study NCT05297799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ameda Pearl breast pump
Description: The Ameda Pearl breast pump is a powered, multi-user breast pump with stimulation and expression modes and independently user-selectable speed and suction control in each mode.
Study NCT05619003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Silicone Sacral dressing
Description: Biatain Silicone Sacral will be applied over the bony prominence of the sacral area
Study NCT04913571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin
Study NCT04913571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab
Study NCT05375370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circulating tumor DNA dosage
Description: blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma
Study NCT05678270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-192
Description: ICP-192 is a round, uncoated tablet, 5mg, orally.
Study NCT04773288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live feedback during handwashing
Description: Live feedback provided during handwashing on display
Study NCT05509062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure
Description: Subjects are randomized to one of three treatment groups
Study NCT06149689 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX plus radiotherapy
Description: Patients with advanced pancreatic adenocarcinoma will receive a modified FOLFIRINOX regimen (oxaliplatin \[70 mg per square meter of body surface area\], irinotecan \[130 mg per square meter\], leucovorin \[200 mg per square meter\], and fluorouracil \[2000 mg per square meter\] every 2 weeks). Four-week chemotherapy is considered as a cycle. Patients will be recommended to receive Intensity-Modulated Radiation Therapy (IMRT) after about 4\~6 cycles of chemotherapy. The following treatment after radiotherapy will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.
Study NCT05365789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blocked Nose Baby nasal spray
Description: One or two nasal sprays will be administered to each nostril for a minimum of 2 times per day up to a maximum of 6 times per day for a maximum of 10 days.
Study NCT05365789 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
Study NCT05365789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care consists of hydration, rest at home and antipyretic paracetamol as necessary.
Study NCT06493643 — intervention group
Intervention type: OTHER
Intervention: Measurement of perfusion index after supraclavicular brachial plexus block at blocked & unblocked limb
Description: The PI (Perfusion Index) was measured using Masimo SET pulse oximetry applied on the index finger. The PI was recorded at baseline and at 10 , 20 , and 30 min after local anaesthetic injection in both the blocked limb and the contralateral unblocked limb using two separate oximeters. The PI ratio was calculated as the ratio between the PI at 10min after injection and the baseline PI. In every patient, a comparison between the blocked and unblocked limb was performed .
Study NCT05703425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine will be administered between 24 and 36 weeks of pregnancy
Study NCT04762992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Enoxaparin
Description: Enoxaparin subcutaneous injections (40 mg, 4000 IU daily) starting immediately after the diagnosis of FGR, and until 36 weeks of gestation or 12 hours before delivery, whichever comes first.
Study NCT04762992 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard of care
Description: Obsteric standard of care.
Study NCT06145659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool and Me
Description: Utilizes patient navigation services and a medical-educational care plan to support linkages between medical and educational systems
Study NCT05216939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flannel mask with ear loops
Description: Participants will have a mask fit test and will wear a flannel mask with ear loops. While wearing the flannel mask, participants will perform a sequence of activities. The researchers will note whether the mask lost its fit (e.g., slipping off the nose or face). Between activities, participants will be told to re-adjust the mask. Participants will be assigned to a specific speed on a treadmill with no incline, either 1.5 mph, the 'light' activity level, or 3 mph, the 'moderate' activity level. They will walk on the treadmill for 10 minutes. Prior to the treadmill activity, participants will rate the comfort and fit of the mask. Near the end of the activity, participants will rate their perceived exertion and again rate the comfort of the mask. Participants will complete a post-experiment questionnaire following all activities.